Development of test kit for detection of specific IgM to SARS-CoV-2 by immune blotting in the «Line blot» format.
Разработка иммуноферментной тест-системы для выявления специфических иммуноглобулинов класса М к коронавирусу SARS-CoV-2 методом иммунного блоттинга в формате «Line blot».
COVID-19
SARS-CoV-2
class M immunoglobulins (IgM)
clinical laboratory diagnostics
enzyme-linked immunosorbent assay (ELISA)
immune blotting (IB)
Journal
Klinicheskaia laboratornaia diagnostika
ISSN: 0869-2084
Titre abrégé: Klin Lab Diagn
Pays: Russia (Federation)
ID NLM: 9432021
Informations de publication
Date de publication:
13 Aug 2021
13 Aug 2021
Historique:
entrez:
13
8
2021
pubmed:
14
8
2021
medline:
18
8
2021
Statut:
ppublish
Résumé
Test kit for detection of specific IgM to SARS-CoV-2 by immune blotting in the «Line blot» format has been developed. A preliminary study of diagnostic effectivity on clinical samples of blood serum from patients with COVID-19 and healthy donors showed its high sensitivity and specificity. The new test kit allows to detect IgM to all four structural antigens of SARS-CoV-2 and can be used as a confirmatory test to verify indeterminant screening results in laboratory etiological diagnosis of COVID-19.
Identifiants
pubmed: 34388317
doi: 10.51620/0869-2084-2021-66-8-472-479
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Immunoglobulin M
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
472-479Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Temporary guidelines “Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)”. Version 11 (05/07/2021) (approved by the Ministry of Health of the Russian Federation on May 07, 2021) [Vremennye metodicheskie rekomendacii «Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)». Versija 11 (07.05.2021) (utv. Ministerstvom zdravoohranenija RF) 07 maya 2021] URL: https://xn--80aesfpebagmfblc0a.xn--p1ai/ai/doc/872/attach/Bmr_COVID-19_compressed.pdf. (in Russian)
WHO temporary guidance «Antigen detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassay» (09/11/2020) [Vremennoye rukovodstvo VOZ «Vyyavleniye antigena v diagnostike infektsii SARS-CoV-2 s pomoshch’yu ekspress-immunoanaliza» (11.09.2020)] URL: https://www.white-product.com/pdf/ВОЗ. Vyyavleniye antigena v diagnostike infektsii SARS-CoV-2 с.pdf. (in Russian)
Ozcurumez M., Ambrosch A., Frey O., Haselmann V., Holdenrieder S., Kiehntopf M. et al. SARS-CoV-2 antibody testing — questions to be asked. J. allergy clin. Immunol. 2020; 146 (1): 35-43.
Sethuraman N., Stanleyraj S., Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. JAMA. 2020; 323 (22): 2249-51.
Watson J., Richter A., Deeks J. Testing for SARS-CoV-2 antibodies. BMJ. 2020; 370: m3325.
Du Z., Zhu F., Guo F., Yang B., Wang T. Detection of antibodies against SARS-CoV-2in patients with COVID-19. J. Med. Virol. 2020; 92 (10): 1735-8.
La Marca A., Capuzzo M., Paglia T., Roli L., Trenti T., Nelson S.M. Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays. Reprod Biomed Online. 2020; 41 (3): 483-99.
McAndrews K.M., Dowlatshahi D.P., Dai J., Becker L.M., Hensel J., Snowden L.M. et al. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity. JCI Insight. 2020; 5 (18): e142386. https://doi.org/10.1172/jci.insight.142386.
Haselmann V., Özçürümez M.K., Klawonn F., Ast V., Gerhards C., Eichneret R. et al. Results of the first pilot external quality assessment (EQA) scheme for anti-SARS-CoV2-antibody testing. Clin Chem Lab Med. 2020; 58 (12): 2121–30.
Mardanly S.G., Avdonina A.S., Mamedova S.G. Development of an enzyme-linked immunosorbent assay for the detection of IgG-antibodies to the causative agent of COVID-19 in human serum (plasma). Klinicheskaya Laboratornaya Diagnostika. 2020; 65 (11): 683-7. (in Russian)
Mardanly S.G. Development and testing of new enzyme-linked immunosorbent assay systems for the diagnosis of toxoplasmosis. Klinicheskaya Laboratornaya Diagnostika. 2009; 2: 35-7. (in Russian)
Mardanly S.G. Epidemiological surveillance of TORCH-group infections based on modern technologies of laboratory diagnostics. Diss. Moscow; 2016. (in Russian)
Mardanly S.G., Simonov V.V., Avdonina A.S. Production of reagent kits for clinical laboratory diagnostics by immunochemical methods. Orekhovo-Zuevo: GGTU; 2017. (in Russian)
Mardanly S.G., Simonova E.G., Simonov V.V. Torch-group infections: clinical laboratory diagnostics, epidemiological surveillance and control. Moscow: Tranzit-IKS; 2018. (in Russian)
Mardanly S.G., Simonova E.G., Simonov V.V. Herpesvirus infections: etiology and pathogenesis, clinical picture and laboratory diagnostics, epidemiology and prevention. Orekhovo-Zuevo: GGTU; 2020. (in Russian)
Brouwer P.J., Caniels T.G., Straten K., Snitselaar J.L., Aldon Y., Bangaru S. et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science. 2020; 369: 643–50.
Shi R., Shan C., Duan X., Chen Z., Liu P., Song J. et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. 2020; 584: 120-4.
Narayanan K., Maeda A., Maeda J., Makino S. Characterization of the coronavirus M protein and nucleocapsid interaction in infected cells. J. Virol. 2000; 74 (17): 8127-34.
Opstelten D.J., Raamsman M.J., Wolfs K., Horzinek M.C., Rottier P.J. Envelope glycoprotein interactions in coronavirus assembly. J. Cell Biol. 1995; 131 (2): 339-49.
Liu J., Sun Y., Qi J., Chu F., Wu H., Gao F. et al. The membrane protein of severe acute respiratory syndrome coronavirus acts as a dominant immunogen revealed by a clustering region of novel functionally and structurally defined cytotoxic T-lymphocyte epitopes. J. Infect. Dis. 2010; 202 (8): 1171-80.
Schoeman D., Fielding B.C. Coronavirus envelope protein: current knowledge. Virol. J. 2019; 16 (1): 69.
Peng H., Yang L., Wang L., Li J., Huang J., Lu Z. et al. Long-lived memory T-lymphocyte responses against SARS coronavirus nucleocapsid protein in SARS-recovered patients. Virology. 2006; 351: 466-75.
Hiscox J.A., Wurm T., Wilson L., Britton P., Cavanagh D., Brooks G. The coronavirus infectious bronchitis virus nucleoprotein localizes to the nucleolus. J. Virol. 2001; 201: 506-12.
Narayanan K., Chen C.J., Maeda J., Makino S. Nucleocapsid independent specific viral RNA packaging via viral envelope protein and viral RNA signal. J. Virol. 2003; 77: 2922-7.
Wang N., Shang J., Jiang S., Du L. Subunit vaccines against emerging pathogenic human coronaviruses. Front. Microbiol. 2020; 11: 298.